Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Aggressive Cancer (R01 Clinical Trial Optional)

The summary for the Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Aggressive Cancer (R01 Clinical Trial Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Aggressive Cancer (R01 Clinical Trial Optional): This Funding Opportunity Announcement (FOA) will support the development and characterization of state-of-the-art projects that include imaging, biomarkers, digital pathomic and other omic data integration strategies for improving current approaches for the earliest detection of premetastatic aggressive cancer as well as identifying precancerous lesions that will subsequently demonstrate an aggressive phenotype. This FOA specifically attempts to address and improve diagnostic uncertainty in clinical decisions in a technology agnostic manner by improving sensitivity and specificity of applied tests. N-dimensional co-registered, cross-correlated imaging data integrated with multiplexed biomarker results and digital pathomics using analytic strategies such as artificial intelligence and virtual reality visualization for improving cancer research discovery are encouraged. The projects supported by this FOA will collectively participate in the existing Consortium for Imaging and Biomarkers (CIB) Research Program. The goals of the CIB are to: (1) improve diagnostic performance by developing methodology for the early identification of lethal cancer versus non-lethal disease, (2) to minimize/better manage overdiagnosis and (3) to reduce false positives and false negatives.
Federal Grant Title: Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Aggressive Cancer (R01 Clinical Trial Optional)
Federal Agency Name: National Institutes of Health (HHS-NIH11)
Grant Categories: Education Health
Type of Opportunity: Discretionary
Funding Opportunity Number: PAR-19-264
Type of Funding: Grant
CFDA Numbers: 93.393, 93.394
CFDA Descriptions: Information not provided
Current Application Deadline: December 10th, 2021
Original Application Deadline: December 10th, 2021
Posted Date: May 1st, 2019
Creation Date: May 1st, 2019
Archive Date: January 15th, 2022
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Last Updated: May 1st, 2019
Applicants Eligible for this Grant
State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement
http://grants.nih.gov/grants/guide/pa-files/PAR-19-264.html
Grant Announcement Contact
NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants
Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)
Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer ...
Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Cli...
Early-Stage Development of Informatics Technologies for Cancer Research and Management (U0...
Pilot Studies in Pancreatic Cancer
Cancer Prevention Research Small Grant Program
Molecular Targets for Nutrients in Prostate Cancer Prevention
More Grants from the National Institutes of Health
HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...
Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allow...
Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optio...
AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com